Background/Purpose Several anti-viral drugs are approved for the treatment of hepatitis B
virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg) …

Background The clinical value of quantitative hepatitis B surface antigen (qHBsAg) titre in
patients taking nucleotide/nucleoside analogues (NAs) is still controversial. This study aims …

Background/Purpose To evaluate whether on-treatment HBV-DNA level could predict the
treatment response to entecavir in hepatitis B e antigen (HBe)-positive chronic hepatitis B …

OBJECTIVES: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients
receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response …

Background Entecavir is a potent nucleoside analogue for treating chronic hepatitis B
(CHB). Quantitative hepatitis B surface antigen (qHBsAg) levels are predictive of response to …

Background: The ultimate goal of hepatitis B treatment is hepatitis B surface antigen
(HBsAg) seroclearance. Several factors have been suggested to be associated with the rate …

Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen
(qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the …

Recent studies have suggested that quantifying the serum HBsAg levels can predict the
response to pegylated interferon. We aimed to determine the change in serum HBsAg levels …

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and
association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving …

AIM To investigate the utility of hepatitis B surface antigen (HBsAg) kinetics in chronic
hepatitis B patients during long-term entecavir treatment. METHODS This retrospective study …